ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Abh3vt, the two stage milestones in Q2 and Q3 is consistent with Harmony's assertion of filing NDA for PITOLISANT GR in Q2, the second milestone is likely the FDA acceptance of the application. The $10 million is likely a Q3 event, revenue for that quarter will also be supported the results of the Acute Gouty Arthritis team.

Regarding potential royalty streams:

The CEO has never articulated this facet of royalty revenue. But Samy Shanmugam, the founder of Novitium (Now ANIP) and Nuray Chemicals, is ANIP's Director and Head of R&D and COO of NJ Operation

The IP from the Harmony deal was acquired from Nuray Chemicals and extends to 2042.

https://patents.google.com/patent/US11945788B2/en?q=(chemicals)&assignee=nuray&oq=nuray+chemicals

I can envision a similar, yet more lucrative deal with Pfizer. Nuray Chemicals also IP regarding an improved version tafamidis (Pfizer's Vyndaquel/ Vyndamax) patent extending to 2041. Incidentally, Matthew Leonard, who sits on ANIP's BOD, joined Pfizer, Inc. in December 2023, as Senior Vice President, Global Access and Value.

https://patents.google.com/patent/US11523993B1/en?q=(chemicals)&assignee=nuray&oq=nuray+chemicals.

ANIP is also still litigating royalty rights from CG Oncology, which I can see this heading to SCOTUS to address the inequities regarding patent erosion while drugs are working their through trial and the approval process.

Finally, there is Libigel. I expect some form of partnership. It will be interesting to see if ANIP is looking at copromotion/co-development deal, or just looking royalties and milestone payments.

Personally, I believe more positive news is coming before the 2027 guidance is provided. But 2027 guidance will still prove important.